Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Clobetasol propionate
Drug ID BADD_D00490
Description Clobetasol propionate is a prednisolone derivative with higher specificity for glucocorticoid receptors than mineralocorticoid receptors.[L11815] It has demonstrated superior activity compared to [fluocinonide][A190963] and was first described in the literature in 1974.[A190936] Clobetasol Propionate was granted FDA approval on 27 December 1985.[L11809]
Indications and Usage Clobetasol propionate is indicated to treat moderate to severe plaque psoriasis[L11818,L118121,L11824] as well as inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.[L11815,L11827]
Marketing Status approved
ATC Code D07AD01
DrugBank ID DB01013
KEGG ID D01272
MeSH ID D002990
PubChem ID 32798
TTD Drug ID D0H0YD
NDC Product Code 79572-008; 42291-077; 50383-267; 51672-4193; 60429-902; 68071-2725; 0472-0403; 70771-1442; 52128-158; 16714-030; 0168-0163; 45802-437; 49502-537; 50383-269; 51672-1259; 62332-486; 63629-2393; 68382-998; 68462-529; 46439-8747; 33342-321; 43386-096; 50742-304; 51672-1258; 0299-3847; 62559-980; 63629-2395; 68462-532; 70700-106; 70710-1401; 71589-002; 0299-3849; 62332-707; 63646-500; 68180-956; 70710-1456; 71589-018; 22552-0006; 13668-569; 43538-952; 43538-953; 45802-925; 50090-5778; 50090-6402; 50383-978; 50383-979; 63629-2329; 63629-2392; 0378-8055; 68071-2764; 68788-8238; 70700-109; 71205-151; 72578-085; 51552-0605; 42571-362; 43538-950; 0168-0269; 50383-268; 51672-1293; 63629-2331; 63629-8637; 69238-1532; 71428-005; 0713-0656; 46439-8708; 49452-2141; 62991-1492; 42291-076; 63629-2332; 0591-4039; 43386-028; 0168-0162; 0168-0301; 50090-5079; 62332-465; 63629-2394; 63629-9461; 0378-8147; 68462-608; 70771-1209; 71085-007; 72189-262; 51927-2627; 40032-028; 0168-0293; 45802-637; 50090-5488; 51672-1350; 62332-548; 63629-2330; 63629-8639; 64980-441; 66993-939; 68180-536; 68462-530; 0472-0404; 70752-153; 70771-1080; 40032-096; 51672-1294; 51672-1371; 0299-3848; 62332-425; 62332-547; 63629-8638; 63629-9460; 68180-551; 68462-480; 68462-625; 69238-1732; 70771-1498; 64958-0101; 76003-0325; 16714-782; 45802-961; 50090-5264; 50383-266; 51672-1297; 51672-1347; 53002-9970
UNII 779619577M
Synonyms Clobetasol | Clofenazon | Clobetasol Propionate | Clobetasol 17-Propionate | Clobetasol 17 Propionate | Clobex | Cormax | OLUX | Dermovate | Embeline | Embeline E | Temovate
Chemical Information
Molecular Formula C25H32ClFO5
CAS Registry Number 25122-46-7
SMILES CCC(=O)OC1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)C(=O)CCl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Dizziness17.02.05.003; 02.11.04.006; 24.06.02.007--
Drug ineffective08.06.01.0060.118010%Not Available
Dry skin23.03.03.001--
Dysgeusia17.02.07.003; 07.14.03.001--
Eczema23.03.04.006--
Erythema23.03.06.0010.017739%Not Available
Eye irritation06.04.05.003--Not Available
Fatigue08.01.01.002--
Folliculitis23.11.04.003; 11.02.01.053--
Fontanelle bulging18.04.04.001; 17.02.05.0060.001867%Not Available
Glaucoma06.03.01.0020.001867%
Glucocorticoids increased13.10.09.003--Not Available
Glycosuria20.02.01.005--
Headache17.14.01.001--
Hepatic steatosis14.08.04.005; 09.01.07.0030.003735%Not Available
Hyperadrenocorticism24.08.02.005; 14.11.01.009; 05.01.01.003--Not Available
Hyperglycaemia14.06.02.002; 05.06.02.002--
Hypersensitivity10.01.03.0030.007282%
Hypertension24.08.02.0010.003735%
Hypertrichosis23.02.04.0020.001867%
Hypoaesthesia23.03.03.081; 17.02.06.023--Not Available
Increased appetite14.03.01.003; 08.01.09.027--Not Available
Infection11.01.08.002--Not Available
Insomnia19.02.01.002; 17.15.03.0020.004108%
Instillation site pain12.07.01.008; 08.02.01.008--Not Available
Kaposi's sarcoma16.33.02.001; 11.05.17.0010.003735%Not Available
Lethargy19.04.04.004; 17.02.04.003; 08.01.01.0080.002801%
Leukoderma23.05.02.001--Not Available
Miliaria23.02.03.014--Not Available
Muscle spasms15.05.03.004--
The 2th Page    First    Pre   2 3 4 5    Next   Last    Total 5 Pages